icon

To say Oncothyreon (ONTY) has been a high-flyer for 2010 is an understatement.

Propelled by the winding down of Stimuvax Phase III trials, this stock has jumped from three bucks to ten in a short amount of time as the investment community started taking notice and predicting that another potential De...

Read more

A temporary price bump sparked by some positive news updates earlier this month put CYTR right back to near the eighty cent range, but not for long as shares closed Monday under seventy cents.

While the news-fueled spike didn't sustain for too long, the quick spike on news is a good indicator that th...

Read more

Earlier this year BioDelivery Sciences (BDSI) announced the completion of enrollment for its ongoing Phase III trial for BEMA Buprenorphine in the treatment of chronic pain, and the next logical step would be the completion of the trial itself.

That news hit the wires on Monday morning.

According to...

Read more

Last month we discussed the fact that Immunocellular Therapeutics could be a company that is priming itself to usher in the next generation of cancer immunotherapeutic treatments, with Dendreon (DNDN) being the obvious leader of the "now" generation.

The reason behind this claim is centered on the co...

Read more

Manhattan Pharmaceuticals is a penny play that has returned some solid gains this year already, on more than one occasion, but like most penny plays, the quick gains were followed by even quicker declines in share prices.

That's why, when playing the pennies, you always need to be on your game and ha...

Read more

MultiCell Technologies is another penny play that has already produced some nice returns for traders this year - and long-termers as well - but like the spikes experienced by Manhattan Pharmaceuticals, the swift gains were followed by even swifter retreats.

While the MultiCell pipeline was stalled t...

Read more

Earlier this month Apricus Biosciences made headlines by announcing the sale of its subsidiary, Bio-Quant CRO, to Bio Tox Sciences for a minimum of $5 million up-front and future payments, with the potential for the deal to be worth as much as $20 million over the next ten years.

As explained in a re...

Read more

As the orders and the backlog grow for Capstone Turbine (CPST), there's another reason to keep an eye on this company that is positioning itself to play a key role in 'fueling the future'.

Capstone announced on Tuesday that it had further penetrated the hospital market by selling one of its C1000 mo...

Read more

A Wednesday morning report by Bloomberg fits right into growing speculation that Titan Pharmaceuticals (TTNP.ob) will eventually be purchased or partnered before Probuphine reaches market. Titan just recently announced positive Phase III confirmatory results for Probuphine, shortly after resolving i...

Read more

Cel-Sci's partner in Isreal for Multikine, Teva Pharmaceutical Industries, kicked off its portion of the global Phase III trial last month, and this week the two companies announced that the existing agreement to market and distribute Multikine in Israel and Turkey would be expanded to also include ...

Read more

According to a press release issued by Epicept Corporation this week, new data published in the July 7, 2011 edition of Blood, a leading scientific journal in hematology, demonstrated that "interleukin-2 (IL-2) monotherapy is not effective as a maintenance therapy for acute myeloid leukemia (AML) pa...

Read more

ChromaDex Corp. is at a pivotal juncture in the company's history, with the commercial launch of its first full product line, BluScience, set to hit GNC stores nationally in August. Earlier predictions had the line hitting GNC in July, but a minor manufacturing delay has pushed the launch back a few...

Read more

Stocks worth keeping an eye on this week. VFC's Stock House has been compensated by a third party to cover CDXC for a period of 90 days.

TTNP: Although reporting milestone news last week with the announcement of positive top-line results for the Probuphine Phase III trial, shares of Titan Pharmaceuti...

Read more

Generex: Hope For A Rebound?

Posted by Posted by VFC on Jul 12, 2011

After having dropped to the low teens, the Generex share price rebounded on huge volume on Friday when the company announced that preliminary results from two trials are demonstrating that Oral-lyn works in patients with Type 1 Diabetes and with patients who have impaired glucose tolerance.

The nearl...

Read more

With the new - and short - trading week opened up, here's a few updates from around the biotech world:

DNDN: After a week full of milestones for Dendreon Corporation (DNDN), shares continued to tick higher and maintained their stance above the forty dollar level as it looks as if the $350-$400 millio...

Read more

As noted in Wednesday morning's 'Biotech Snapshot', CytRx is on a roll of positive pipeline progress that has brought a bit of a rebound to the CYTR share price, which has modestly declined over the past few weeks.

Wednesday morning brought another dose of positive updates when it was announced that ...

Read more

The last time we discussed Bioelectronics Corp, the company had just posted fourth quarter 2010 and first quarter 2011 sales numbers to its homepage - numbers that demonstrated growth, but not significant enough to support a price run back to over a penny.

With a novel idea that is still developing i...

Read more

It'll be a short trading week after a long weekend, but there's still always stories to tell...

TTNP: Titan Pharmaceuticals (TTNP.ob) provided quick resolution to the potentially troubling concerns of the prior weekend when the FDA indicated that it wanted to alter the Statistical Analysis Plan (SAP)...

Read more

As shares of SIGA dip below the ten dollar mark, it might be time to take full notice of what's going on with the stock and what might be ahead.

Less than two months ago SIGA was again awarded a BARDA contract to supply the nation's biodefense stockpiles with its ST-246 antiviral. Again, however, the...

Read more